(NASDAQ: VYGR) Voyager Therapeutics's forecast annual revenue growth rate of 33.85% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Voyager Therapeutics's revenue in 2026 is $36,494,000.On average, 13 Wall Street analysts forecast VYGR's revenue for 2026 to be $2,964,932,974, with the lowest VYGR revenue forecast at $953,327,066, and the highest VYGR revenue forecast at $7,975,005,671. On average, 13 Wall Street analysts forecast VYGR's revenue for 2027 to be $4,069,011,152, with the lowest VYGR revenue forecast at $1,184,257,225, and the highest VYGR revenue forecast at $7,799,179,726.
In 2028, VYGR is forecast to generate $5,317,798,311 in revenue, with the lowest revenue forecast at $1,184,257,225 and the highest revenue forecast at $14,085,410,425.